Liminatus Pharma, Inc.
LIMN
$5.54
-$0.61-9.92%
NASDAQ
| 03/31/2024 | |||||
|---|---|---|---|---|---|
| Net Income | -127.50% | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | -- | ||||
| Change in Net Operating Assets | 95.13% | ||||
| Cash from Operations | -173.35% | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -49.25% | ||||
| Cash from Investing | -49.25% | ||||
| Total Debt Issued | -14.29% | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -- | ||||
| Cash from Financing | -3.00% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -199.03% | ||||